In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes. Ai Ng SY, Zhu D, Herrington WG. Ann Intern Med 2020;172:JC18.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ai Ng SY, Zhu D, Herrington WG. In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes. Ann Intern Med 2020;172:JC18.
PMID: 32066151